Hormonal Aging Is Not Destiny: A Physician's Framework

Hormonal aging is the gradual change in hormone systems — growth hormone, sex hormones, thyroid and others — that contributes to loss of muscle, gain in abdominal fat, slower recovery and lower energy over time. It is common, but it is not a fixed destiny: much of it is shaped by sleep, body composition, fitness and treatable medical conditions, and some true deficiencies can be safely corrected with proven therapies. The goal is not to chase youthful lab numbers, but to protect function in the right order.

Hormonal Aging Is Real, but Not the Whole Story

Several hormone systems change with age:

• Growth hormone (GH) and IGF-1. The pituitary releases GH in pulses, mostly during deep sleep. Those pulses become smaller with age, and IGF-1 — produced mainly by the liver in response to GH — tends to fall.
• Testosterone. Many men experience a gradual decline, accelerated by obesity, poor sleep, chronic illness, alcohol and certain medications.
• Estrogen and progesterone. Women go through a more abrupt transition at menopause, with effects on hot flashes, sleep, bone, mood and cardiovascular risk.
• Thyroid, cortisol and insulin. These change less predictably, but insulin resistance in particular becomes more common with age and inactivity.

It is tempting to describe all of this as "hormonal decay" and to treat every symptom as a hormone problem. That framing goes too far. Loss of muscle is driven heavily by inactivity and low protein intake; fatigue often reflects sleep apnea, depression, anemia or thyroid disease; and abdominal weight gain both results from and causes hormonal changes. Treating hormones without addressing these drivers usually disappoints.

A Physician's Framework for Hormonal Aging

In my practice, I use a simple sequence. Each step builds on the one before it.

1. Measure properly

Hormone tests are easy to misinterpret. Testosterone should be measured in the morning, ideally fasting, and confirmed on a second occasion. IGF-1 needs age-specific interpretation. Thyroid tests are affected by illness and supplements such as biotin. Menopause is primarily a clinical diagnosis. A careful baseline also includes a blood count, metabolic panel, lipids, HbA1c and screening for sleep apnea.

2. Fix the foundation

The most powerful influences on the hormone systems are not prescriptions:

• Sleep. Most GH release happens in deep sleep, and sleep restriction lowers testosterone and worsens insulin resistance.
• Resistance training. Strength training is the most reliable way to preserve muscle and bone with age.
• Body composition. Losing excess abdominal fat often improves testosterone in men and insulin sensitivity in everyone. FDA-approved medications such as semaglutide and tirzepatide can help when obesity is present.
• Nutrition and alcohol. Adequate protein supports muscle; heavy alcohol use suppresses several hormone systems.

3. Treat true deficiencies with proven therapies

When evaluation confirms a deficiency, established treatments have real evidence:

• Testosterone therapy for men with confirmed hypogonadism. The TRAVERSE trial found no increase in major cardiovascular events compared with placebo in men with hypogonadism and high cardiovascular risk, though it reported more atrial fibrillation, acute kidney injury and pulmonary embolism. Monitoring is essential; see TRT Monitoring: A Complete Physician Guide.
• Menopausal hormone therapy for bothersome symptoms. Current position statements support it as the most effective treatment for hot flashes in appropriate candidates, particularly when started before age 60 or within 10 years of menopause. See Hormone Optimization for Women Over 40.
• Thyroid treatment when hypothyroidism is confirmed — not for borderline numbers alone. More in Thyroid Optimization for Longevity.

4. Consider investigational options carefully, if at all

This is where much online content jumps first. Growth hormone secretagogues such as CJC-1295 and ipamorelin act on two receptors that both stimulate GH release, and together they produce a larger GH pulse than either alone. The biology is sound. But human data are limited to short-term studies of hormone levels, neither compound is FDA-approved, and as of this writing neither can be legally compounded in the U.S. after FDA's advisory committee voted against them in 2024. I explain the details in CJC-1295 + Ipamorelin: The Growth Hormone Axis Explained.

Tesamorelin, a related growth hormone-releasing hormone analog, is FDA-approved, but only for reducing excess abdominal fat in people with HIV-associated lipodystrophy.

Other compounds are often marketed as part of a multi-front "anti-aging" program — MOTS-c for metabolism, BPC-157 for tissue repair. Their human evidence is early or minimal, and their regulatory status is in flux: an FDA advisory committee recommended both for the compounding list in July 2026, but FDA rulemaking is still pending. Check current FDA guidance, and treat any claim of dramatic results with skepticism.

The IGF-1 and Cancer Question

Some sources dismiss concerns about raising IGF-1 as baseless. I do not think that is the right approach. Higher IGF-1 levels have been associated with higher risk of some cancers, including prostate, breast and colorectal, in observational studies. That does not prove that raising IGF-1 causes cancer, and IGF-1 is better understood as a growth-promoting signal than a cause of cancer on its own. But long-term safety data for GH-axis peptides in healthy adults do not exist.

The reasonable position is in between: avoid GH-stimulating therapies in anyone with active or recent cancer, keep IGF-1 within an age-appropriate range if therapy is used, keep cancer screening up to date, and recognize what we do not yet know.

What "Not Destiny" Really Means

Hormonal aging is not a sentence of inevitable decline, and it is not a problem to be solved with a long list of injections. It means that many of the changes people accept as "normal aging" can be measured, understood and improved — often substantially — through foundations and proven therapies. At Laeeq M.D., that is the order we follow, with investigational options discussed only after evaluation and labs and with dosing always individualized.

Sources

• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline — Bhasin S, et al. Journal of Clinical Endocrinology & Metabolism, 2018
• Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) — Lincoff AM, et al. New England Journal of Medicine, 2023
• The 2022 hormone therapy position statement of The North American Menopause Society — Menopause, 2022

Book a Consultation

If you are noticing changes in energy, strength, body composition or sleep and want to understand what is driving them, start with a thorough evaluation. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA. Book a consultation to review your history, labs and goals.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.